Abstract

High But Inequitable COVID-19 Vaccine Uptake Among Patients with Inflammatory Bowel Disease

Clin Gastroenterol Hepatol. 2022 Jul;20(7):1606-1608.e2. doi: 10.1016/j.cgh.2021.12.013.Epub 2021 Dec 9.

 

Trevor L Schell 1Luke J Richard 1Katharine Tippins 1Rachel K Russ 1Mary S Hayney 1Freddy Caldera 2

 
     

Author information

1Division of Gastroenterology and Hepatology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.

2Division of Gastroenterology and Hepatology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. Electronic address: fcaldera@medicine.wisc.edu.

Abstract

Coronavirus disease 2019 (COVID-19) vaccines are recommended for all patients with inflammatory bowel disease (IBD).1 Patients with IBD historically have had low vaccine uptake relative to the general population.2 However, a recent survey suggested a rate higher than that of the general population with regard to COVID-19 vaccine intent among the IBD population. Their study was limited being that 96% of the patients surveyed identified as White, and 88% had attained a bachelor's degree or higher level of education.3 Therefore, these findings may not be representative of the IBD population as a whole. Previous studies have indeed identified disparities in influenza vaccine uptake within the IBD population.4,5.

 

© Copyright 2013-2022 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.